Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sihuan Pharma Trades At 28 Percent Above IPO Target; Analysts Point To Risks

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's Sihuan Pharmaceutical Holdings Group far exceeded its target price in its debut on the Hong Kong stock market, ending the first day with shares trading at 28 percent above the price

You may also be interested in...



Sihuan And Other Leading Chinese Drug Firms Could Get Boost From Current Meeting Of National People's Congress In Beijing

BEIJING - Sihuan Pharmaceutical Holdings Group, based on the tropical Chinese island of Hainan, could see a sharp upward trajectory in earnings over the next three years as it continues to expand its product portfolio through acquisitions fueled by proceeds raised during its initial public offering and a government push to consolidate the Chinese pharmaceutical industry

Sihuan And Other Leading Chinese Drug Firms Could Get Boost From Current Meeting Of National People's Congress In Beijing

BEIJING - Sihuan Pharmaceutical Holdings Group, based on the tropical Chinese island of Hainan, could see a sharp upward trajectory in earnings over the next three years as it continues to expand its product portfolio through acquisitions fueled by proceeds raised during its initial public offering and a government push to consolidate the Chinese pharmaceutical industry

China Biopharma IPOs Skyrocket In 2010 After Freeze Is Lifted

HONG KONG - The number of initial public offerings by pharmaceutical and biotech companies in China continued to rise in 2010, continuing a surge in IPOs that started in mid-2009

Related Content

Latest News
UsernamePublicRestriction

Register

SC073696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel